Nuvation Bio (NUVB) Stock Forecast, Price Target & Predictions
NUVB Stock Forecast
Nuvation Bio stock forecast is as follows: an average price target of $7.00 (represents a 189.26% upside from NUVB’s last price of $2.42) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NUVB Price Target
The average price target for Nuvation Bio (NUVB) is $7.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 189.26% upside from NUVB's last price of $2.42.
NUVB Analyst Ratings
According to 4 Wall Street analysts, Nuvation Bio's rating consensus is 'Buy'. The analyst rating breakdown for NUVB stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nuvation Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Robert Burns | H.C. Wainwright | $7.00 | $3.05 | 129.51% | 189.26% |
| Apr 17, 2024 | Kennen MacKay | RBC Capital | $5.00 | $2.81 | 77.94% | 106.61% |
| Mar 28, 2024 | Robert Burns | H.C. Wainwright | $8.00 | $3.97 | 101.51% | 230.58% |
| Mar 27, 2024 | Michael Yee | Jefferies | $10.00 | $2.88 | 247.22% | 313.22% |
| Mar 26, 2024 | Kaveri Pohlman | BTIG | $5.00 | $2.25 | 122.22% | 106.61% |
| Jan 06, 2023 | Jefferies | $2.00 | $2.03 | -1.48% | -17.36% | |
| May 04, 2022 | H.C. Wainwright | $14.00 | $4.78 | 192.89% | 478.51% |
The latest Nuvation Bio stock forecast, released on Sep 16, 2024 by Robert Burns from H.C. Wainwright, set a price target of $7.00, which represents a 129.51% increase from the stock price at the time of the forecast ($3.05), and a 189.26% increase from NUVB last price ($2.42).
Nuvation Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 5 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.42 | $2.42 | $2.42 |
| Upside/Downside | -100.00% | -100.00% | 189.26% |
In the current month, the average price target of Nuvation Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nuvation Bio's last price of $2.42. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 07, 2025 | RBC Capital | Outperform | Outperform | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Mar 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 27, 2024 | Jefferies | Hold | Buy | Upgrade |
| Mar 26, 2024 | BTIG | Buy | Upgrade | |
| Jan 07, 2023 | Jefferies | Hold | Downgrade |
Nuvation Bio's last stock rating was published by RBC Capital on Jan 07, 2025. The company gave NUVB a "Outperform" rating, the same as its previous rate.
Nuvation Bio Financial Forecast
Nuvation Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $8.92M | $3.46M | $727.00K | $727.00K | $727.00K | $727.00K | $1.44M |
| High Forecast | $8.92M | $3.46M | $727.00K | $727.00K | $727.00K | $727.00K | $1.44M |
| Low Forecast | $8.92M | $3.46M | $727.00K | $727.00K | $727.00K | $727.00K | $1.44M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - |
Nuvation Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NUVB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nuvation Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NUVB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nuvation Bio's previous annual EBITDA (undefined) of $NaN.
Nuvation Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-41.51M | $-42.35M | $-41.24M | $-38.95M | $-36.47M | $-34.47M | $-14.31M |
| High Forecast | $-41.51M | $-42.35M | $-41.24M | $-36.17M | $-31.26M | $-34.47M | $-14.31M |
| Low Forecast | $-41.51M | $-42.35M | $-41.24M | $-41.73M | $-44.29M | $-34.47M | $-14.31M |
| Surprise % | - | - | - | - | - | - | - |
Nuvation Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NUVB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nuvation Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvation Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NUVB last annual SG&A of $NaN (undefined).
Nuvation Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.15 | $-0.15 | $-0.15 | $-0.14 | $-0.13 | $-0.13 | $-0.06 |
| High Forecast | $-0.15 | $-0.15 | $-0.15 | $-0.13 | $-0.11 | $-0.13 | $-0.06 |
| Low Forecast | $-0.15 | $-0.15 | $-0.15 | $-0.15 | $-0.16 | $-0.13 | $-0.06 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Nuvation Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NUVB previous annual EPS of $NaN (undefined).
Nuvation Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $0.86 | $10.00 | 1062.79% | Buy |
| TIL | Instil Bio | $26.31 | $150.00 | 470.13% | Hold |
| CTMX | CytomX Therapeutics | $0.82 | $3.47 | 323.17% | Buy |
| NXTC | NextCure | $0.80 | $3.00 | 275.00% | Buy |
| NUVB | Nuvation Bio | $2.42 | $7.00 | 189.26% | Buy |
| ASMB | Assembly Biosciences | $13.86 | $35.50 | 156.13% | Buy |
| ACHL | Achilles Therapeutics | $1.13 | $2.00 | 76.99% | Buy |